预防和治疗1型糖尿病的免疫疗法
1Division of Endocrinology, Diabetes & Metabolism, University of Louisville, Louisville, KY, USA.
Immunotherapy
|March 4, 2025
概括
1型糖尿病 (T1D) 涉及自身免疫性破坏胰岛素产生细胞. 免疫调节疗法,如teplizumab,旨在延迟T1D发病和管理并发症,为患者提供新的希望.
科学领域:
- 免疫学 免疫学 免疫学
- 内分泌学 在内分泌学.
- 自身免疫性疾病是一种自身免疫性疾病.
背景情况:
- 1型糖尿病 (T1D) 是由胰腺β细胞的自身免疫破坏引起的,需要终身胰岛素治疗.
- 目前的糖尿病技术改善了管理,但T1D患者仍然面临严重并发症的风险,如低血糖和糖尿病酸性糖尿病.
- 以前针对T1D的免疫调节方法在预防或治疗疾病方面表现出有限的有效性.
研究的目的:
- 审查1型糖尿病的历史和当前免疫调节策略.
- 突出针对T1D预防和治疗的基于免疫的干预措施的进展.
- 讨论像特普利祖马布 (teplizumab) 这样的疗法在治疗T1D中的作用.
主要方法:
- 对1型糖尿病的免疫调节疗法发表文献的综述.
- 对针对T1D免疫系统的干预措施的临床试验数据的分析.
- 检查关键免疫调节剂,包括单克隆抗体的作用机制.
主要成果:
- 一种抗CD3单克隆抗体Teplizumab被批准用于延迟T1D的发病.
- 目前正在对T1D进行研究的其他各种免疫调节干预措施.
- 尽管取得了进展,但在基于免疫的T1D疗法中实现广泛的疗效仍然是一个挑战.
结论:
- 免疫调节疗法是1型糖尿病管理和预防的有希望的途径.
- 德普利祖马布的批准标志着延迟T1D发病的重要里程碑.
- 对新型免疫调节方法的持续研究对于未来的T1D治疗至关重要.
相关概念视频
Diabetes Mellitus: Overview and Type I Subtype
2.3K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.3K
Diabetes Mellitus: Type 2 and Gestational
2.1K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.1K
Diabetes: Management and Pharmacotherapy
227
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
227
Tumor Immunotherapy
461
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
461
Oral Hypoglycemic Agents: Biguanides and Glitazones
151
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
151
Insulin: Dosing Regimen and Adverse Effects
137
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
137


